Sign in →

Test Code HITIG Heparin-PF4 IgG Antibody (HIT), Serum

Secondary ID

86533

Useful For

Detection of IgG antibodies directed against heparin/platelet factor 4 complexes that are implicated in the pathogenesis of immune-mediated type II heparin-induced thrombocytopenia (HIT-II).

 

Clinical picture of HIT type II:

-In patients not previously exposed to heparin

-Decrease in platelet count (thrombocytopenia) of 50% or more from baseline or postoperative peak

-Onset of thrombocytopenia beginning approximately 5 to 10 days after initiation of heparin this may or may not be associated with new or progressive thrombosis in patients treated with heparin

 

Patients previously exposed to heparin (especially within the preceding 100 days), in addition to the above findings, the onset of thrombocytopenia could occur within 24 to 48 hours after reexposure to heparin

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Heparin-PF4 IgG Ab (HIT), S

Specimen Type

Serum Red


Specimen Required


Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 14 days
  Refrigerated  48 hours

Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

Mild OK; Gross reject

Icterus

NA

Other

Serum gel tube

Clinical Information

Thrombocytopenia in patients treated with heparin is relatively common and has diverse, sometimes multifactorial, causes. Among the possible causes of thrombocytopenia in such patients, immune-mediated heparin-dependent thrombocytopenia (HIT) is clinically important because of its frequency and its associated risk of paradoxical new or progressive thrombosis.

 

HIT, also called heparin-associated thrombocytopenia (HAT), consists of 2 distinct clinicopathologic syndromes. The first, sometimes designated type I HIT (HIT-I) or nonimmune HAT, is a common benign condition that is not immunologically mediated. Type I HIT is characterized by a mild decrease of the platelet count (typically ≤30% decrease from baseline) occurring early (days) in the course of treatment with heparin, especially intravenous unfractionated heparin (UFH), and which does not progress and may resolve despite continuation of heparin therapy.

 

The second, more serious immune-mediated syndrome, sometimes designated type II heparin-induced thrombocytopenia (HIT-II), occurs in up to 1% to 5% of patients treated with UFH. It is typically characterized by onset of thrombocytopenia between days 5 and 10 of UFH therapy, but thrombocytopenia can arise earlier or later in association with continued heparin exposure. In patients recently exposed to heparin (eg, within the preceding 3-6 months), onset of thrombocytopenia can be rapid (within 24 hours) after heparin reexposure, probably reflecting persistence of heparin-dependent antiplatelet antibodies or anamnestic recall of them. Typically, during the course of HIT-II, the platelet count decreases by at least 40% to 50% from baseline or the postoperative peak (in surgical patients), even though the absolute count may remain normal, and thrombocytopenia resolves within 7 to 14 days of cessation of heparin therapy (unless there is another coexisting cause of thrombocytopenia). The risk of immune-mediated HIT-II is significantly greater with UFH exposure than with exposure to low-molecular-weight heparin (LMWH), although the latter can react with heparin-dependent antibodies induced by UFH. The risk is probably also associated with the dosage and route of heparin administration (eg, intravenous), as well as associated medical and surgical conditions. 

 

HIT-II is clinically important, not because of the mild or moderate thrombocytopenia and minimal bleeding risk, but because of the high risk for development of paradoxical thrombosis (arterial or venous) that may be new or progressive. This evolution, termed heparin-induced thrombocytopenia with thrombosis (HITT) syndrome, can occur in up to 30% to 50% of patients with HIT-II, even following discontinuation of heparin therapy. Clinically, it is often difficult to distinguish between HIT-I and HIT-II and among other etiologies of thrombocytopenia occurring in patients receiving heparin. However, the development of new or progressive thrombosis is one defining clinical feature of HIT-II.

 

Recent studies provide evidence that HIT-II is caused, in at least 90% of cases, by antibodies to antigen complexes of heparinoid (heparin or similar glycosaminoglycans) and platelet factor 4 (PF4). PF4 is a platelet-specific heparin-binding (neutralizing) protein that is abundant in platelet alpha granules from which it is secreted following platelet stimulation. A reservoir of PF4 normally accumulates upon vascular endothelium. Following heparin administration, immunogenic complexes of PF4 and heparin can provide an antigenic stimulus for antibody development in some patients. Antibodies bound to platelets that display complexes of PF4/heparin antigen can activate platelets via interaction of the Fc immunoglobulin tail of the IgG antibody with platelet Fc gamma IIA receptors, leading to perpetuation of the pathologic process that can cause platelet-rich thrombi in the microcirculation in some cases (eg, HITT syndrome).

 

Functional assays for HIT-II antibody detection rely on antibody-mediated heparin-dependent platelet activation, as detected by platelet aggregation, or platelet secretion of serotonin or adenosine triphosphate (ATP) or other substances, using patient serum or plasma supplemented with heparin and normal test platelets from carefully selected donors. The sensitivity of functional assays for HIT-II ranges from 50% to 60% for heparin-dependent platelet aggregation (HDPA) assays, to 70% to 80% for serotonin release assays. The specificity of positive functional tests for HIT diagnosis is believed to be high (≥90%). However, because of their complexity, functional tests for detecting HIT antibodies are not widely available.

 

Enzyme-linked immunosorbent assays (ELISAs) have recently been developed to detect HIT-II antibodies and are based on the detection of human antibodies that react with solid phase antigen complexes of heparinoid and human PF4 (H/PF4 complexes). The ELISA for H/PF4 antibodies is very sensitive for antibody detection, but relatively nonspecific for clinical HIT diagnosis.

 

Routine screening of all patients prior to, during, or following heparin use is currently not recommended. A positive H/PF4 ELISA result has relatively low and uncertain predictive value for the development of clinical HIT-II.

Reference Values

HIT ELISA:

<0.400

 

HIT Interpretation:

Negative

Interpretation

Results are reported as: 1) Heparin-induced thrombocytopenia (HIT) enzyme-linked immunosorbent assay (ELISA) OD; 2) Heparin inhibition (%); 3) Interpretation. Typical patterns of results and interpretations are depicted in the following table. Interpretive comments will also accompany test reports, when indicated.

 

 

HIT ELISA OD

Heparin Inhibition

Interpretation

Normal Range

<0.400

Not done

Negative

Positive

≥0.400

≥50%

Positive

Equivocal

≥0.400

<50%

Equivocal

 

A negative result of testing for human platelet factor 4 (H/PF4) antibodies has about a 90% negative predictive value for exclusion of clinical type II heparin-induced thrombocytopenia (HIT-II).

 

Because up to 10% of patients with clinical heparin-induced thrombocytopenia (HIT) may have a negative H/PF4 antibody ELISA result, a negative H/PF4 antibody ELISA result does not exclude the diagnosis of HIT when clinical suspicion remains high. A functional assay for HIT antibodies (eg, heparin-dependent platelet aggregation or serotonin release assay may be helpful in these circumstances). Contact Mayo Medical Laboratories for ordering information.

 

A positive result is indicative of the presence of H/PF4 complex antibodies. However, this test's specificity is as low as 20% to 50% for clinical diagnosis of HIT, depending on the patient population studied. For example, up to 50% of surgical patients and up to 20% of medical patients treated with heparin may develop H/PF4 antibodies as measured by ELISA, and only a small proportion (1%-5%) develop clinical HIT. Accordingly, this test does not confirm the diagnosis of HIT-II. The diagnosis must be made in conjunction with clinical findings, including evaluation for other potential causes of thrombocytopenia.

 

The presence of H/PF4 antibodies likely increases the risk of clinical HIT, with risk probably partly dependent on associated medical and surgical conditions, but currently there are few data about relative risk of HIT in various populations with positive tests for H/PF4 antibodies.

Clinical Reference

1. Heparin Induced Thrombocytopenia. Edited by TE Warkentin, A Greinacher. New York, Marcel Dekker, 2000, p 400

2. Trossaert M, Gaillard A, Commin PL, et al: High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998 June;101(4):653-655

Day(s) and Time(s) Performed

Monday through Friday; a.m. and p.m. runs

Saturday through Sunday; a.m. run only

Analytic Time

1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

86022

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HITIG Heparin-PF4 IgG Ab (HIT), S In Process

 

Result ID Test Result Name Result LOINC Value
46915 HIT ELISA In Process
21468 Heparin Inhibition 73817-9
21469 HIT Interpretation 69049-5
21470 HIT Comment 48767-8